Peru
Hepatitis B
Download HBV dataHBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
System for monitoring testing and treatment
Not Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Recommendations for HBV testing of pregnant women
Adopted
HBV testing policy
Risk-based
Licensed point-of-care PCR testing to detect HBV
Adopted
Eligible for HBV generic medicines
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
System for monitoring testing and treatment
Not Adopted
Recommendations for HCV testing of pregnant women
Not Adopted
HCV testing policy
Risk-based
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Adopted
Eligible for HCV generic medicines
Yes
Registration of originator HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
No
% of substance use disorder facilities offering hepatitis treatment
No
Public budget line for testing and treatment
Adopted
Hepatitis C
Download HCV dataHBV National Action Plan
HBV elimination goal
National prevalence survey within the last 5 years
Partially Adopted
Estimates of economic burden
Partially Adopted
System for monitoring testing and treatment
Not Adopted
HepB birth dose policy
Yes
Year of birth dose introduction
2000
Recommendations for HBV testing of pregnant women
Adopted
HBV testing policy
Risk-based
Licensed point-of-care PCR testing to detect HBV
Adopted
Eligible for HBV generic medicines
Public budget line for testing and treatment
Adopted
HCV National Action Plan
HCV elimination goal
System for monitoring testing and treatment
Not Adopted
Recommendations for HCV testing of pregnant women
Not Adopted
HCV testing policy
Risk-based
National treatment guidelines exist
Adopted
Simplified care: Non-specialists can prescribe treatment
Adopted
No fibrosis restrictions
Adopted
No sobriety restrictions
Adopted
Eligible for HCV generic medicines
Yes
Registration of originator HCV DAAs
Adopted
Licensed point-of-care PCR testing to detect HCV
Adopted
At least one needle-syringe exchange program (NSP) operational
No
At least one opioid substitution therapy (OST) program operational
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
No
% of substance use disorder facilities offering hepatitis treatment
No
Public budget line for testing and treatment
Adopted
Overview
HBV elimination goal
HCV elimination goal
Prevalence (national)
Modelled
Survey/surveillance
Hepatitis related deaths (national)
Modelled
HBV
846
2019
(581 - 1,186)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HBV chart
Modelled
HCV
887
2019
(563 - 1,334)
IHME, GBD 2019 (accessed 2022)
Survey/surveillance
No data available
HCV chart
Prevalence < 5
HBV
0.06
(%)
2020, latest modelled
(0.05 - 0.07(%))
WHO
Prevalence PWID
No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines
Yes